science wire

« BACK

Pharmacology



Results 301 - 350 of 1876.
« Previous 1 ... 3 4 5 6 7 8 9 10 11 ... 38 Next »


Health - Pharmacology - 15.01.2020
Genome editing at the crossroads of scandal and cure
Genetic modification of babies in China one year ago was universally condemned. At the same time, CRISPR treatments are on their way into our clinics.

Health - Pharmacology - 14.01.2020
New heart disease drug to be made available to NHS patients through ground-breaking collaboration
Up to 30,000 lives could be saved over the next decade thanks to a proposed pioneering government collaboration with pharmaceutical company Novartis to tackle heart disease - a leading cause of death in the UK.

Pharmacology - Health - 13.01.2020
Project aims to improve diagnosis and treatment for patients with anaemia
Ambulatory care specialists at the University of Birmingham, with support from Vifor Pharma UK Limited (VPUK), are working to develop and implement a population based anaemia diagnosis and treatment decision support service for routine healthcare delivery.

Pharmacology - Health - 10.01.2020
New partnership with international pharmaceutical company provides up to $10 million for drug development research at U-M
New partnership with international pharmaceutical company provides up to $10 million for drug development research at U-M
The University of Michigan and Sun Pharma Advanced Research Company have launched a partnership to accelerate the development of potential new medicines for a wide range of diseases. The new venture will provide up to a total of $10 million in financial support and in-kind industry resources to move various promising drug-discovery research projects within the university toward the ultimate goal of new therapies for patients.

Health - Pharmacology - 10.01.2020
Cancer researchers call for ambitious survival targets for the 2020s
The NHS should raise their five-year lung cancer survival targets to 35% by 2030, concludes a new 'state of the nation' policy report conducted by UCL.

Health - Pharmacology - 09.01.2020
First patient for Parkinson's disease trial recruited
First patient for Parkinson’s disease trial recruited
The trial, funded by a 2.1 million grant from the National Institute for Health Research (NIHR) , will test whether a commonly prescribed dementia drug could prevent debilitating falls for people with the disease.

Pharmacology - Health - 09.01.2020
Contaminating a fake rubber hand could help people overcome OCD
Contaminating a fake rubber hand could help people overcome OCD
For Cambridge students For our researchers Business and enterprise Colleges and Departments Email and phone search Give to Cambridge Museums and collections Undergraduate Events and open days Fees an

Health - Pharmacology - 09.01.2020
One out of every two transplant recipients at risk of infection
One out of every two transplant recipients at risk of infection
Swiss researchers, including UNIGE, show that 50% of transplant recipients develop severe infections within a year of the operation, which can lead to death.

Pharmacology - Health - 09.01.2020
Novartis ligelizumab (QGE031) more effective than Xolair at inhibiting immunoglobulin E pathway responsible for chronic spontaneous urticaria
Patients & Caregivers Healthcare Professionals Society & ESG Data show ligelizumab binds to immunoglobulin E (IgE), a key driver of chronic spontaneous urticaria (CSU), with significantly hig

Health - Pharmacology - 08.01.2020
Heart patients in China may be receiving substandard hospital care
A new study suggests that China needs a national strategy to improve hospital care for heart patients. The study, a collaboration among researchers in China and the United States, appears Jan. 8 in the journal JAMA Network Open. Harlan Krumholz, M.D., cardiologist and director of the Yale Center for Outcomes Research and Evaluation (CORE), is co-senior author of the study along with Chinese researcher Jing Li, M.D. The Chinese government has made heart patient care a priority in the past decade, initiating extensive health care reforms.

Pharmacology - Pedagogy - 23.12.2019
Parents: Turkey makes great leftovers-opioids do not
Leftover prescription opioids pose big risks to kids, yet most parents keep their own and their child's unused painkillers even after they're no longer medically necessary for pain.

Pharmacology - 23.12.2019

Pharmacology - Health - 19.12.2019
New MERS vaccine clinical trial starts in Saudi Arabia
The King Abdullah International Medical Research Centre (KAIMRC), in collaboration with the University of Oxford's Jenner Institute has started a Phase I clinical trial in the Kingdom of Saudi Arabia (KSA) for a vaccine against Middle East Respiratory Syndrome Coronavirus (MERS-CoV).

Health - Pharmacology - 19.12.2019
Sugar not to blame for high risk of heart disease in those at high risk for diabetes
Patients at high risk for diabetes are also at a high risk for heart disease - but not because of higher sugar levels, according to new research led by the University of Glasgow.

Pharmacology - Health - 16.12.2019
Novartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthma
Patients & Caregivers Healthcare Professionals Society & ESG Pooled analyses of LUSTER 1 and 2 did not support further development of Fevipiprant in asthma as a primary indication Fevipipra

Pharmacology - Health - 16.12.2019

Pharmacology - Health - 13.12.2019
Novartis receives positive CHMP opinion for Beovu (brolucizumab) for the treatment of wet AMD
Patients & Caregivers Healthcare Professionals Society & ESG In two head-to-head clinical trials, patients on Beovu achieved vision gains that were non-inferior to aflibercept at year one 1

Pharmacology - Health - 13.12.2019
Roche announces positive Phase III study results for Tecentriq plus Cotellic and Zelboraf in people with previously untreated BRAF V600 mutation-positive advanced melanoma
Roche today announced the Phase III IMspire150 study, in people with previously untreated BRAF V600 mutation-positive advanced melanoma, met its primary endpoint of progression-free survival (PFS).

Pharmacology - Health - 12.12.2019
Graphene Industry Showcase comes to Manchester
![CDATA[ This week Graphene@Manchester hosted a jam-packed two-day (10-11 December) event showcasing the hottest topics in the field of graphene.

Pharmacology - Health - 12.12.2019
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Fixed-dose combination administered under the skin in just minutes, compared to hours with intravenous administration, significantly reducing time spent receiving treatment Phase III FeDeriCa study s

Health - Pharmacology - 11.12.2019
Novartis Kisqali data show superior overall survival compared to fulvestrant and consistent efficacy across advanced breast cancer patient subgroups in MONALEESA-3
Patients & Caregivers Healthcare Professionals Society & ESG MONALEESA-3 paper published today in The New England Journal of Medicine shows statistically significant overall survival results

Pharmacology - Health - 11.12.2019
APHINITY six-year results strengthen evidence of clinical benefit with Roche’s Perjeta-based regimen
Greatest improvement in invasive disease-free survival (iDFS) remains in patients at high risk of recurrence, such as those with lymph node-positive disease with a 28% reduction in the risk of recurr

Health - Pharmacology - 10.12.2019
Roche receives CE Mark for its Accu-Chek SugarView app
Accu-Chek SugarView is the first app that determines blood glucose ranges by taking photos with the smartphone camera without the need of a blood glucose meter.

Pharmacology - Health - 09.12.2019
Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting
Patients & Caregivers Healthcare Professionals Society & ESG Efficacy in DLBCL confirmed results seen in the pivotal trial despite treatment of a broader population, including older and more

Health - Pharmacology - 09.12.2019
Novartis global survey uncovers profound and often under-reported effects on sickle cell disease patients
Patients & Caregivers Healthcare Professionals Society & ESG Findings from more than 2,000 respondents in 16 countries underscore the debilitating and under-reported effects of sickle cell di

Pharmacology - Health - 08.12.2019
New data demonstrate the continued clinical benefit of fixed-duration, chemotherapy-free Venclexta/Venclyxto-based treatments in chronic lymphocytic leukaemia
In an updated analysis of the CLL14 study, Venclexta/Venclyxto plus Gazyva/Gazyvaro achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukaemia

Pharmacology - Health - 06.12.2019
Novartis Phase III data on new inhaled dual combination QMF149 show significant improvement across key asthma outcomes versus monotherapy
Patients & Caregivers Healthcare Professionals Society & ESG Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versu

Pharmacology - Chemistry - 06.12.2019
At 14, U-M undergrad dazzles researchers with scientific prowess
At 14, U-M undergrad dazzles researchers with scientific prowess
oe中文 हिन्दी Portugus Español Share on: Share on Twitter Share on Facebook Share on LinkedIn When 14-year-old Daniel Liu buttons his lab coat and goes to work, he transforms from a teenager into a fearless and persistent researcher.

Pharmacology - Health - 04.12.2019
FDA approves Roche’s Tecentriq plus chemotherapy (Abraxane and carboplatin) for the initial treatment of metastatic non-squamous non-small cell lung cancer
Approval based on the Phase III IMpower130 study showing the Tecentriq plus chemotherapy combination demonstrated a significant overall survival and progression-free survival benefit Roche today anno

Health - Pharmacology - 03.12.2019

Pharmacology - Health - 02.12.2019
Novartis breadth of data at 2019 ASH demonstrates commitment to reimagining medicine in hematology through innovative therapeutic platforms
Patients & Caregivers Healthcare Professionals Society & ESG With more than 140 abstracts, Novartis continues its leadership in hematology innovation Data for MBG453, an innovative anti-TIM

Health - Pharmacology - 02.12.2019

Health - Pharmacology - 02.12.2019
Improving Tuberculosis Screening in Remote Areas
Improving Tuberculosis Screening in Remote Areas
Every year, 1.5 million people die from tuberculosis (TB) worldwide. Diagnosis and treatment is particularly difficult in remote rural areas.

Pharmacology - Health - 02.12.2019
Positive phase III results for Roche’s satralizumab in neuromyelitis optica spectrum disorder published in the New England Journal of Medicine
Satralizumab demonstrated robust efficacy, sustained for 144 weeks, in significantly reducing the risk of relapse in combination with baseline immunosuppressant therapy Satralizumab targets the interleukin-6 (IL-6) receptor, a potential key driver of neuromyelitis optica spectrum disorder (NMOSD) NMOSD is a rare, debilitating autoimmune disease of the central nervous system that can cause visual impairment, motor disability and even death Roche

Health - Pharmacology - 29.11.2019
In Birmingham could improve outcomes for people at risk of dangerous blood clots
New University of Birmingham research funded by the British Heart Foundation could improve treatments for a potentially deadly condition that affects tens of thousands of people in the UK each year.

Health - Pharmacology - 27.11.2019
Podcast: Vaping concerns, medical detection dogs, and a visit to CERN
In this edition: We explore the possible harms of vaping, meet dogs trained to detect disease, and travel through the physics of CERN.

Pharmacology - Health - 25.11.2019
FDA grants priority review to Roche’s risdiplam for spinal muscular atrophy
Filing submission includes 12-month data from pivotal FIREFISH and SUNFISH trials in a broad population of people living with Types 1, 2 or 3 SMA Roche today announced that the U.S. Foo
« Previous 1 ... 3 4 5 6 7 8 9 10 11 ... 38 Next »

This site uses cookies and analysis tools to improve the usability of the site. More information. |